TREATMENT OF BLOOD CLOTTING DISORDERS

Before beginning fertility treatments, the patient’s blood coagulation is determined (APC Resistance or Factor V Leiden).

In general, there is a differentiation between low and high-risk patients:

• Low-risk patients are advised to take blood-thinning medication during treatment in the case of having additional risk factors such as obesity, varicose veins or old age.
• High-risk patients are advised to use blood-thinning medication from the start of treatment and up to six weeks after giving birth.

If thrombophilia, i.e. an increased tendency for thrombosis, is diagnosed, treatment can be initiated in the family planning phase with the used of blood-thinning medication such as Thrombo ASS 100 or heparin injections. As a result, there can be better care of the unborn child and a miscarriage due to a blood clotting disorder can be avoided.

During fertility treatment or an existing pregnancy, heparin is used because it does not pass through the placenta into the child’s blood, where it could cause malformations. Heparin is only available in the form of syringes, which the patient can administer under the skin.

‘Blood thinners’ also include acetylsalicylic acid (ASA). It has the same active ingredient that is found in aspirin. ASA works differently than heparin. It does not – like heparin -change the interaction of coagulation proteins, but reduces the functionality of the blood platelets (thrombocytes). The flowability of the blood is not influenced either.